➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Moodys
Boehringer Ingelheim
Express Scripts
Baxter

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

HYDROGEN PEROXIDE - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic sources for hydrogen peroxide and what is the scope of patent protection?

Hydrogen peroxide is the generic ingredient in one branded drug marketed by Aclaris and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Hydrogen peroxide has thirty patent family members in seventeen countries.

There are fifty-three drug master file entries for hydrogen peroxide.

Summary for HYDROGEN PEROXIDE
International Patents:30
US Patents:6
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 53
Bulk Api Vendors: 133
Clinical Trials: 83
Patent Applications: 5,330
Formulation / Manufacturing:see details
Drug Prices: Drug price trends for HYDROGEN PEROXIDE
What excipients (inactive ingredients) are in HYDROGEN PEROXIDE?HYDROGEN PEROXIDE excipients list
DailyMed Link:HYDROGEN PEROXIDE at DailyMed
Drug Prices for HYDROGEN PEROXIDE

See drug prices for HYDROGEN PEROXIDE

Drug Sales Revenue Trends for HYDROGEN PEROXIDE

See drug sales revenues for HYDROGEN PEROXIDE

Recent Clinical Trials for HYDROGEN PEROXIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Pontificia Universidad JaverianaPhase 2/Phase 3
Hospital Universitario San IgnacioPhase 2/Phase 3
The University of Texas Health Science Center, HoustonPhase 4

See all HYDROGEN PEROXIDE clinical trials

Medical Subject Heading (MeSH) Categories for HYDROGEN PEROXIDE

US Patents and Regulatory Information for HYDROGEN PEROXIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No   Start Trial   Start Trial   Start Trial
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No   Start Trial   Start Trial   Start Trial
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No   Start Trial   Start Trial Y   Start Trial
Aclaris ESKATA hydrogen peroxide SOLUTION;TOPICAL 209305-001 Dec 14, 2017 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for HYDROGEN PEROXIDE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2523731 24/2020 Austria   Start Trial PRODUCT NAME: OSILODROSTAT ODER PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, EINSCHLIESSLICH OSILODROSTATDIHYDROGENPHOSPHAT; REGISTRATION NO/DATE: EU/1/19/1407 (MITTEILUNG) 20200113
3106463 CR 2020 00013 Denmark   Start Trial PRODUCT NAME: LAROTRECTINIB OG/ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT LAROTRECTINIBSULFAT, INKLUSIV LAROTRECTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20190923
0281459 98C0036 France   Start Trial PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
0281459 35/1998 Austria   Start Trial PRODUCT NAME: CLOPIDOGREL-HYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/98/069/001 - EU/1/98/069/003 19980715
3106463 122020000012 Germany   Start Trial PRODUCT NAME: LAROTRECTINIB UND/ODER ANDERE PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, INSBESONDERE LAROTRECTINIBSULFATE UMFASSEND LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190919
0605697 SPC/GB01/008 United Kingdom   Start Trial PRODUCT NAME: 1-(((3-(2-(DIMETHYLAMINO)ETHYL)INDOL-5-YL)METHYL)SULFONYL)PYRROLIDINE GENERIC NAME ALMOTRIPTAN, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY AS ALMOTRIPTAN D,L - HYDROGEN MALATE; REGISTERED: ES 62.877 19991223; UK PL 16973/0005 20001026
2787345 CR 2016 00055 Denmark   Start Trial PRODUCT NAME: MIGALASTAT ELLER ET SALT HERAF, HERUNDER HYDROGENKLORIDSALTET; REG. NO/DATE: EU/1/15/1082 20160531
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
McKesson
Express Scripts
Moodys
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.